A published paper by Dr. Li and colleagues[@bib0001] revealed that the elevated levels of creatine kinase-MB (CK-MB) were associated with the severity of coronavirus disease 2019 (COVID-19) patients. Recently, several emerging papers have focused on the association of the CK-MB levels with the risk of mortality in COVID-19 infected patients. However, the conclusions drawn from different studies are inconsistent.[@bib0002], [@bib0003], [@bib0004] In order to obtain a definitive conclusion on the association between the levels of CK-MB and the risk of mortality in COVID-19 patients, a quantitative meta-analysis was conducted on the basis of published data.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was strictly enforced throughout the design and implementation of this meta-analysis.[@bib0005] Chinese National Knowledge Infrastructure, Web of Science and PubMed databases were extensively searched by 2 of the authors (Li Shi and Ying Wang) prior to May 5, 2020 with the following keywords: "characteristics," "clinical," "laboratory," "SARS-CoV-2," "2019-nCoV," "COVID-19," "coronavirus 2019," "outcome," "death," and "mortality." The mean and standard deviation could be estimated by sample size, median and interquartile range according to Wan et al\'s paper.[@bib0006] The screening criterion was that studies provided mean (standard deviation) or median (interquartile range) for levels of CK-MB in both non-survival and survival COVID-19 infected patients. The pooled standardized mean difference and 95% confidence interval were used to assess the effect sizes, since the units of CK-MB are different among the eligible studies.[@bib0007] We chose different models based on the incongruity index (*I^2^; I^2^* \< 50% for the fixed-effects model; *I^2^* ≥ 50% for the random-effects model).[@bib0008] In addition, sensitivity analysis was performed by sequentially omitting single study to test the stability of our final results.[@bib0009] The potential presence of publication bias was examined by Begg\'s regression test and Egger\'s linear regression test.[@bib0010] ^,^ [@bib0011] All statistical analyses were conducted by using the Stata 11.2 software package (StataCorp, College Station, Texas). p \< 0.05 was regarded as statistical significance.

Five studies performed in China were finally included in this meta-analysis through detailed screening of 1,630 studies. A total of 1,170 COVID-19 infected patients including 280 non-survivors and 890 survivors were from the First People\'s Hospital of Jiangxia District,[@bib0003] Renmin Hospital,[@bib0012] Tongji hospital,[@bib0013] Jinyintan Hospital,[@bib0004] Zhongnan Hospital and Xishui Hospital.[@bib0002] More details of the included studies are demonstrated in [Table 1](#tbl0001){ref-type="table"} .Table 1Characteristics of the included studiesTable 1AuthorLocationCaseNonsurvival patientsSurvival patientsnAge (years)Malecreatine kinase-MBnAge (years)MaleCreatine kinase-MBWang D et al.[@bib0002]China1071973.0 (64.0-81.0)16 (84%)18 (13-44) U/L8844.5 (35.0-58.8)41 (47%)13 (9-16) U/LWang K et al.[@bib0003]China2961965.6±12.611 (58%)17.5 (16.7-28.1) U/L27746.0±14.4129 (47%)13.5 (11.4-17.1) U/LWang L et al.[@bib0012]China3396576 (70-83)39 (60%)2.95 (1.30-4.30) ng/mL27468 (64-74)127 (46%)1.15 (0.81-1.91) ng/mLWang Y et al.[@bib0013]China34413370 (62-77)74 (56%)2.5 (1.2-6.1) ng/mL21157 (47-69)105 (50%)0.4 (0.3-1.2) ng/mLWu C et al.[@bib0004]China844468.5 (59.3-75.0)29 (66%)17.00 (13.00-20.00) U/L4050.0 (40.3-56.8)31 (78%)16.00 (13.00-20.75) U/L[^2]

Due to the high heterogeneity (*I^2^* = 86%, p \< 0.001), we chose a random-effects model to conduct this synthetic analysis. The overall results showed that the elevated levels of CK-MB were significantly associated with an increased risk of the mortality in COVID-19 infected patients (standardized mean difference 0.99; 95% confidence interval 0.57 to 1.42; p \< 0.001; [Figure 1](#fig0001){ref-type="fig"} ). As indicated in [Figure 1](#fig0001){ref-type="fig"}, no single study was found to have obvious effects on the overall results, which suggests the stability of our results. As for the publication bias, both Begg\'s test (p = 0.806) and Egger\'s test (p = 0.642; [Figure 1](#fig0001){ref-type="fig"}) exhibited that there was no publication bias in our present meta-analysis.Figure 1Forest plot (A), sensitivity analysis (B) and Egger\'s test (C) of creatine kinase-MB levels in non-survival COVID-19 patients vs. survival COVID-19 patients.Figure 1

Patients with severe pneumonia have varying degrees of myocardial injury due to hypoxemia and toxicity of the pathogen.[@bib0014], [@bib0015], [@bib0016] So do patients with COVID-19.[@bib0001] ^,^ [@bib0017] ^,^ [@bib0018] CK-MB mainly exists in the outer plasma layer of myocardial cells, and is the most specific enzyme in the myocardial enzyme spectrum for clinical diagnosis of myocardial injury.[@bib0019] ^,^ [@bib0020] A previous meta-analysis by Li et al observed that the elevated CK-MB levels were associated with the severity of COVID-19 patients.[@bib0001] Our present meta-analysis suggests that the elevated levels of CK-MB were significantly associated with an increased risk of the mortality in COVID-19 infected patients.

**C**onflicts of interest**:** All the authors declare that they have no any potential conflicts of interest.

Funding: This study was supported by a grant from the National Natural Science Foundation of China (No. 81973105).

[^1]: Li Shi and Ying Wang contributed equally to this work.

[^2]: All values are n (%), median (IQR), or mean ± SD.
